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Altered glomerular extracellular matrix synthesis in experimental
membranous nephropathy. Chronic progressive membranous nephrop-
athy (MN) in humans is characterized by thickening of the glomerular
basement membrane (GBM) with formation of spikes which contain
laminin and other extracellular matrix (ECM) proteins. We have
utilized two models of MN in the rat (active and passive Heymann
nephritis, AICN, PHN) to define the sequential changes in composition
of GBM as they relate to changes in glomerular gene expression for
ECM components, altered permeability and morphological changes.
Renal biopsies obtained during the course of AICN and PHN were
immunostained for various ECM proteins and total glomerular RNA
was hybridized with cDNA probes specific for laminin B2-chain,
s-laminin, and types I and IV collagen. In addition, the ability of
anti-glomerular epithelial cell (GEC) antibody and complement on rat
GEC in culture to induce laminin release or laminin and s-laminin
mRNA expression was determined. The results demonstrate that at
weeks 12, 16, and 20 of AICN, immunostaining for laminin, s-Iaminin,
fibronectin, entactin, and heparan sulfate proteoglycan increased in the
GBM in a spike-like pattern. Concomitantly, glomerular mRNA levels
of laminin B2-chain and of s-laminin increased. Type IV collagen
protein and gene expression remained unchanged or decreased. No
glomerular immunostaining for type I collagen occurred during AICN
despite increased expression of mRNA for this collagen type. In
contrast to AICN, in PHN no pronounced changes of the glomerular
ECM occurred, except for transient expression of type I collagen
rnRNA in whole glomerular RNA and type I collagen protein the GEC
cytoplasm. Stimulation of GEC in culture with anti-GEC antibody and
complement also failed to induce transcription of laminin or s-laminin
mRNA or the release of laminin protein. These findings suggest that the
polyantigenic expansion of GBM which occurs in chronic experimental
MN may be stimulated by factors different from the C5b-9 mediated
processes that cause the initial proteinuria.
Membranous nephropathy (MN) is the most common cause
of idiopathic nephrotic syndrome in adults [1]. In about 50% of
cases the lesion is a progressive one leading to renal failure [1].
MN is induced by the formation of immune deposits in an
exclusively subepithelial distribution accompanied by deposits
of the complement components C3 and C5b-9 [reviewed in 2—5].
In early MN, glomerular morphology by light microscopy is
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essentially normal. However, as the disease progresses, it is
characterized by increased thickness of the glomerular capillary
wall due to expansion of the glomerular basement membrane
(GBM). This expansion appears to result primarily from in-
creased deposition of extracellular matrix (ECM) along the
outer surface of the GBM, usually in the form of spike-like
protrusions of the GBM between glomerular epithelial cells
(GEC) [5—9]. Some studies have suggested that laminin is a
principal component of the expanded GBM [10, 11] whereas
others have revealed a more heterogeneous composition of the
spikes [12, 13]. This thickened GBM exhibits persistent abnor-
mal permeability to serum proteins and may lose ultrafiltration
properties as well [14, 15].
The pathogenesis of MN has been extensively studied in the
Heymann nephritis models in rats which bear striking similar-
ities in morphology, immunopathology and clinical features to
the human disease. In these models MN results from deposition
of antibody (anti-Fx 1 A) to antigen(s) on the visceral GEC
membrane, and altered GBM permeability is the consequence
of insertion of C5b-9 into the GEC membrane [reviewed in 4,51.
Like the human disease, chronic Heymann nephritis (autolo-
gous immune complex nephritis, AICN) exhibits progressive
GBM thickening and spike formation [6]. The purpose of the
present study was to evaluate the contribution of distinctive
components of the normal ECM to the increased GBM thick-
ness in chronic experimental MN, to assess sequential changes
in glomerular ECM gene expression as they relate to functional
and structural glomerular changes in this model and to evaluate
the possible role of C5b-9 attack on the GEC in vivo and in vitro
in inducing these changes. Since it is impossible to maintain
complement depletion for extended periods in vivo, and since
no rats genetically deficient in terminal complement compo-
nents exist, the latter studies were carried out in the short term,
passive Heymann nephritis (PHN) model as well as in rat GEC
in culture. Our findings demonstrate that a polyantigenic expan-
sion of the GBM occurs in AICN and that laminin and a
recently described analogue of the laminin B1-chain, s-laminin
[16], are prominent ECM proteins contributing to this expan-
sion. Furthermore, the data show that GBM thickening is
preceded by increased laminin and s-laminin gene expression in
AICN, but not in PHN, and that sublytic C5b-9 attack has no
demonstrable effect on GEC release of laminin and laminin or
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s-laminin gene expression. These results suggest that the mech-
anism(s) responsible for progressive glomerular disease in MN
may differ from those which mediate proteinuria acutely.
Methods
Experimental design
In vivo studies. AICN was induced in 30 Lewis rats (see
below). Twenty-four-hour urine protein excretion was deter-
mined at weeks 0, 4, 6, 12, 16 and 20. Urine protein excretion
was measured by a method utilizing sulfosalicylic acid [17] with
a whole serum standard (Lab Trot, Dade Diagnostics, Aquado,
Puerto Rico, USA). Following the urine collection, renal biop-
sies were obtained from four randomly selected rats at each
time point.
PHN was induced in 24 Sprague Dawley rats (see below). Six
normal rats and six rats that were depleted of complement with
cobra venom factor (CVF) prior to induction of PHN were
studied as controls. Twenty-four-hour urinary protein excretion
was determined in the six normal rats, in six randomly selected
PHN rats each at days 2 through 3, 4 through 5, 9 through 10
and 14 through 15, as well as in the PHN/CVF rats at days 4
through 5. After the urine collections rats were sacrificed and
renal biopsies were obtained.
Following the renal biopsies glomeruli were isolated from the
remaining kidney tissue using a differential sieving procedure
[18]. Two (AICN) or three (PHN) separate glomerular prepara-
tions were performed at each time point. The isolated glomeruli
contained less than 5% tubular contamination at any time point
and were used for the extraction of total RNA for Northern
analysis.
The glomerular morphology was analyzed in PAS and silver
methenamine stained sections of the renal biopsies. Further-
more, the renal biopsies were analyzed immunohistochemically
for the glomerular distribution of IgG, C3, C5b-9 as well as the
ECM proteins laminin, s-laminin, type I and IV collagen,
fibronectin, entactin/nidogen, and heparan sulfate proteogly-
can. Northern blots were probed using cDNAs specific for
laminin B2-chain, s-laminin, type I and IV collagen, and 28S
rRNA.
In vitro studies. Using cultured rat GECs, studies were
performed to investigate the effect of anti-Fx1A or normal
sheep IgG plus complement on the cellular release of laminin.
Laminin released into the cell culture medium was measured
using a specific enzyme-linked immunosorbent assay (ELISA;
see below). Expression of laminin B2-chain and s-laminin
mRNA was analyzed in total cellular RNA obtained from
non-stimulated GEC or GEC subjected to sublytic antibody and
complement exposure.
Induction of passive Heymann nephritis and autologous
immune complex nephritis
AICN was induced by immunizing male Lewis rats (Simon-
son, Gilroy, California, USA), weighing 180 to 220 g, in the rear
foot pads with 5 mg freshly prepared Fx1A emulsified in
complete Freund's adjuvant (Difco Laboratories, Detroit,
Michigan, USA) as described previously [19].
PHN was induced in male Sprague-Dawley rats (Tyler Lab-
oratories, Bellevue, Washington, USA) weighing 190 to 210 g,
by i.v. injection of I ml sheep antibody to Fx1A prepared as
described in detail elsewhere [20].
Complement depletion
Rats were depleted of complement with CVF (Naja naja
kaounthia, Diamedix Corporation, Miami, Florida, USA) [21].
Serum C3 levels, obtained daily, were measured by radial
immunodiffusion [21] and maintained at <10% of baseline
values throughout the study period.
Renal morphology
Tissue for light microscopy and immunoperoxidase staining
was fixed in methyl Carnoy's solution [18] and embedded in
paraffin. Four pm sections were stained with the periodic acid
Schiff (PAS) reagent and counterstained with hematoxylin.
Sections were also stained with silver methenarnine to assess
glomerular ECM changes.
Immunoperoxidase staining
Four pm sections of methyl Carnoy's fixed biopsy tissue
were processed by a direct or indirect immunoperoxidase
technique as previously described [18]. Primary antibodies
included:
-an IgG fraction of polyclonal rabbit anti-rat laminin
(Chemicon, Temecula, California, USA). Alterna-
tively a biotinylated [22] IgG fraction of this antibody
was used.
-D18, a monoclonal murine antibody specific for the
laminin B2-chain (gift of J. Sanes, St. Louis, Missouri,
USA) [23].
-D5, a monoclonal mouse anti-rat s-laminin antibody
(gift of J. Sanes) [16].
-an IgG fraction of polyclonal guinea pig anti-rat type
I collagen [24].
-a biotinylated [22] IgG fraction of polyclonal goat
anti-mouse type IV collagen (Southern Biotech, Bir-
mingham, Alabama, USA).
-an affinity-purified IgG fraction of a polyclonal rabbit
anti-rat fibronectin (Chemicon).
-an IgG fraction of polyclonal rabbit anti-mouse entac-
tin/nidogen (gift of A.E. Chung, Pittsburgh, Pennsyl-
vania, USA) [25].
-an IgG fraction of a polyclonal rabbit antibody to
mouse core protein of heparan sulfate proteoglycan
(gift of J.R. Couchman, Birmingham, Alabama, USA)
[26].
For all biopsies, negative controls consisted of substitution of
the primary antibody with equivalent concentrations of an
irrelevant murine monoclonal antibody or normal rabbit IgG.
For each biopsy over 20 cross sections of consecutive corti-
cal glomeruli containing more than 20 discrete capillary seg-
ments each were evaluated by an observer, who was unaware
of the origin of the slides. Glomerular staining for type I
collagen was quantitatively assessed by counting the cells
located in the periphery of the capillary loop which exhibited
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positive cytoplasmic staining and expressed as positive cells!
glomerular cross section.
Immunofluorescence staining for glomerular rat IgG, C3,
C5b-9, and type I collagen
Immunofluorescence detection of rat IgG, C3, C5b-9, and
type I collagen in glomeruli was carried out on 4 xm sections of
frozen, ether/ethanol fixed kidney tissue using a direct (rat IgG,
C3) or indirect (C5b-9, type I collagen) immunofluorescence
procedure, as described elsewhere [19, 27]. Sections were
studied with fluorescein-conjugated IgG fractions of monospe-
cific antisera to rat IgG, and rat C3 (Cappel Laboratories,
Cochraneville, Pennsylvania, USA) and biotinylated [2212Al, a
murine monoclonal antibody to a neoantigen of C5b-9 [28],
followed by fluorescein-conjugated streptavidin (Amersham,
Arlington Heights, Illinois, USA).
Electron microscopy
Tissue for electron microscopy was fixed, processed and
examined as described previously [29]. Ultrastructural studies
were performed on three specimens each obtained at week 4, 8,
12, 16, and 20 (3 to 6 glomeruli were evaluated in each
specimen).
Rat GEC culture
Rat GEC were established in culture from isolated glomeruli
as described previously [30]. Morphological and immunofluo-
rescent characterization of the cells demonstrated a polygonal
shape with cobblestone appearance upon confluency, positive
immunostaining with anti-Fx1A, and anti-cytokeratin, but no
staining with anti-factor VIII or anti-Thy 1.1 [30]. Furthermore,
in contrast to a recent report [311 on the characterization of cells
obtained from glomerular outgrowths, the cultured GEC used
for this study also stained positive for podocalyxin, a marker of
visceral GEC [30]. Finally, puromycin aminonucleoside exhib-
ited toxic effects on the cells [30].
GEC were maintained in 100 mm tissue culture dishes (Bec-
ton Dickinson, Lincoln Park, New Jersey, USA), coated with a
bovine dermal collagen matrix (Vitrogen®, Collagen Corpora-
tion, Palo Alto, California, USA). The cell culture medium
consisted of Kl medium [321. Cells were passaged with colla-
genase and trypsin/EDTA as described [30].
GEC release of laminin following antibody and complement
mediated injury
GEC (passages 12 to 21) were seeded into 24-welt tissue
culture dishes (Corning Glass Works, Corning, New York,
USA) and allowed to reach subconfluency in Kl medium.
Following washing with cold veronal buffered saline [33], the
cells were incubated with anti-FxIA or normal sheep IgG (4
mg/mI) for 15 minutes on ice to allow binding of antibody to the
cells without patching and capping of the antigen-antibody
complexes [34—36]. This concentration of antibody was selected
on the basis of pilot studies which demonstrated it provided the
maximal amount of antibody IgG binding to GEC in culture
without inducing cytotoxicity as assessed by lactate dehydro-
genase (LDH) release (see below). After duplicate washing with
veronal buffered saline, 2% pooled normal, fresh frozen human
serum or heat-inactivated serum (30 mm at 56°C) in veronal
buffered saline was added as a complement source. This serum
concentration was selected as the highest concentration that
cells sensitized with maximal sublytic antibody concentrations
could be exposed to without any cytotoxicity as assessed by
LDH release (see below). Cells were then incubated at 37°C for
90 minutes. Thereafter, the supernatant was removed and the
LDH concentration was determined (see below). The cells were
washed twice with Hank's balanced salt solution (Irvine Scien-
tific, Santa Ana, California, USA) and then incubated for 72
hours in K1 medium at 37°C, 5% CO2 and 100% humidity.
Further controls included non-stimulated cells and cells stimu-
lated for 72 hours with 5 x l0— M!ml phorbol 12-myristate
13-acetate (PMA; Sigma, St. Louis, Missouri, USA). In some
studies the effects of differences in times and temperature of
both antibody and complement exposure were tested as were
variations in incubation times after antibody and complement
exposure. At the end of the incubation period the supernatants
were collected and stored at —70°C for laminin determination.
Laminin concentrations per experiment represent the mean of 3
to 6 individual measurements. Each individual laminin mea-
surement was normalized for cell numbers as measured by the
DNA content (see below) of the corresponding cell layer.
For the determination of the cellular DNA content, the cell
layers were harvested by removing the Vitrogen gel into a
microfuge tube. Following an incubation at 65°C for three
minutes to liquify the gel, the tubes were centrifuged (11,000 g,
5 minutes) and the pellet was then resuspended in 10 mii Tris
buffer, pH 7.4 and stored at —70°C. The DNA content of the
resuspended pellets was determined using a colorimetric diphe-
nylamine assay [371.
The cellular release of LDH into the medium was determined
at 90 minutes (see above) and at the end of the incubation period
(72 hr) to ensure that the experiments had been carried out
under conditions that did not cause any direct cytotoxicity.
LDH was measured using a colorimetric test kit (LDH-LD;
Sigma).
Laminin ELISA
A laminin ELISA was established using principles described
previously [28]. Briefly, wells of microtitration plates (Nunc,
Roskilde, Denmark) were coated with 15 ng of the primary
antibody (an IgG fraction of a polyclonal rabbit anti-rat laminin
antibody, Chemicon). After blocking of the wells with 0.2%
casein (Sigma), the samples were added. The samples were
followed by 0.15 g/we1l secondary antibody (=biotinylated
[22] primary antibody). Bound secondary antibody was de-
tected with streptavidin-peroxidase (Vector, Burlingame, Cali-
fornia, USA) and subsequent color development using acino-
di-[3-ethylbenzthiazolinsulphonate (6)] (ABTS; Boehringer,
Mannheim, Germany). Purified murine laminin (Gibco, Gaith-
ersburg, Maryland, USA) served as a standard. The assay gave
linear readings at laminin concentrations between 1.5 and 100
ng!ml. The detection limit of the ELISA was 1.0 ng!ml laminin
and the intra-assay coefficient of variation was <1%. The
ELISA failed to detect 100 ng!ml of rat type I and III collagen
(a gift of H. Sage, Seattle, Washington, USA), murine type IV
collagen (Collaborative Research, Bedford, Massachusetts,
USA), rat fibronectin (Chemicon), or K! medium.
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Preparation of GEC and glomerular RNA and Northern
analysis
Total RNA was extracted from GEC's or isolated glomeruli
with RNAzo1 B® following the manufacturer's instructions
(CinnalBiotecx Laboratories, Friendswood, Texas, USA) and
further purified by a LiCI precipitation as described elsewhere
[38]. For Northern analysis the RNA was denatured and 15
g/1ane were electrophoresed through a formaldehyde/agarose
gel and transferred to a nylon filter (Hybond N, Amersham) as
described elsewhere [391. The eDNA probes used for Northern
analysis were as follows:
(1) Laminin B2 chain. A 1.7 kb ECO RI/Xba I fragment of
mouse laminin B2 cDNA isolated from plasmid p1298 was used
to detect the 8 kb laminin B2 transcript [40]. The probe was a
gift of Y. Yamada, Bethesda, Maryland, USA.
(2) s-Laminin. A 2.5 kb ECO RI fragment from cDNA clone
RK65-6 from a rat kidney library was used to detect the 5.7 kb
s-laminin mRNA transcript [161. The probe was a gift of J.
Sanes.
(3) Type I collagen. An ECO RI/Hind III fragment of mouse
al(I)collagen from eDNA clone Mal(I)3'UTR of 2.3 kb was
used to detect the 5.7 and 4.7 kb transcripts of type I collagen
[411. The probe was a gift of M. Chu, Piscataway, New Jersey
and J. Slack, Seattle, Washington, USA.
(4) Type IV collagen. A 1.8 kb ECO RI/Hind III fragment of
mouse al(IV)collagen cDNA from plasmid pPE 123 was used
for the detection of the 6.2 and 6.8 type IV collagen transcripts
[42]. The probe was a gift of M. Kurkinen, Piscataway, New
Jersey, USA.
(5) 28S ribosomal RNA. A bovine 280 bp cDNA probe was
used to detect 28S ribosomal RNA [43].
All probes were labeled with [a-32P]-deoxycytidine 5-triphos-
phate (3000 Ci/mmol, New England Nuclear, Boston, Massa-
chusetts, USA) by random primer extension. In preliminary
experiments all of these probes have been shown to crosshy-
bridize with the respective rat mRNAs. Positive controls in-
cluded total RNA isolated from BALB/c 3T3 fibroblasts (type I
collagen), mouse F9 cells (type IV collagen and laminin B2
chain) and rat aortic smooth muscle cells (s-laminin).
Membranes were prehybridized and hybridized as described
[39] and autoradiograms were obtained and read by linear
densitometry [39]. Some membranes were rehybridized with
additional probes (up to a maximum of 4 x) [39].
Quantitation of mRNA
Glomerular mRNA levels were quantified by slot blot analy-
sis prepared with 2, 1 and 0.5 ig of each RNA sample and
control RNAs as described [38]. Densitometry readings were
normalized for equivalent amounts of 28S ribosomal RNA per
lane [39]. Values are expressed as optical density units relative
to the specific mRNA level observed in RNA from normal
glomeruli or non-stimulated GEC.
Statistical analysis
All values are expressed as mean SD unless stated other-
wise. Statistical significance (defined as P < 0.05) was evalu-
ated using the Student's t-test or one way analysis of variance
with modified t-tests performed using the Bonferroni correction
[44].
Results
Immunostaining for ECM proteins in normal rats
In normal Lewis or Sprague Dawley rats, laminin, type IV
collagen, and fibronectin were detected in the mesangium in a
focal manner (Fig. la,g,i). Although the glomerular and tubular
basement membranes showed either weak or non-detectable
staining (Fig. la,g,i), all of these antibodies showed reactivity
with the GBM when used on cryostat sections with an immu-
nofluorescent method. We have previously shown that immu-
nofluorescent staining of cryostat sections is more sensitive
than the immunoperoxidase method in detecting antigens in the
GBM [45]. However, the intense staining of GBM by immuno-
fluorescence for a number of antigens, including type IV
collagen, laminin and fibronectin, prevented the reproducible
analysis of small variations. Immunoperoxidase staining was
therefore utilized in the present study. Immunostaining for
s-laminin resulted in minimal mesangial staining although it
could be frequently detected in the hilus of the glomerular tuft
(Fig. lc). As in the case of laminin, immunofluorescent staining
for s-laminin showed bright positivity in the GBM [45]. Staining
for type I collagen was confined to the interstitium and vessel
walls and was absent in normal glomeruli (Fig. le). Staining for
entactin/nidogen was confined to vessel walls with minimal or
absent mesangial staining [45] (data not shown). Mesangial
staining for heparan sulfate proteoglycan was variable, and
positive staining of the GBMs was observed in most glomeruli
using the immunoperoxidase method (Fig. 1k),
Development of AICN
An increase in urine protein excretion was first detectable in
some AICN rats at week 6, although this was not significantly
different from controls (30 28 mg/24 hrs vs. 4 3 mg124 hrs
in normal Lewis rats). Thereafter, significant proteinuria (P <
0.05 vs. controls) persisted with values of 291 119 mg/24
hours at week 12 and 263 186 mg/24 hours at week 20. As
previously described [27], all proteinuric AICN rats exhibited
typical subepithelial immune deposits of rat IgG, C3 and C5b-9.
By light microscopy there was no significant abnormalities in
glomerular morphology until week 12. Progressive silver meth-
enamine staining of an irregularly widened GBM showing
"spikes" was noted at weeks 12 and 20 (data not shown).
Furthermore, at weeks 12 and 20 enlargement of the glomerular
tuft areas was observed (Fig. lb,d,f,h). Electron microscopy
demonstrated areas of new basement membrane accumulation
around immune deposits in biopsies obtained as early as eight
weeks after disease induction (Fig. 2a). Accumulation of new
basement membrane matrix, including organization into distinct
"spikes", was progressive by twenty weeks (Fig. 2b). This
accumulated GBM matrix frequently surrounded and appeared
to incorporate the subepithelial immune deposits into the un-
derlying GBM (Fig. 2b).
ECM protein immunostaining in glomeruli of rats with AICN
Glomerular and, in particular, GBM immunostaining for both
laminin and s-laminin did not show significant changes from the
normal staining pattern prior to week 12. A progressive increase
in immunostaining for both laminin and s-laminin in the wid-
ened GBM was observed in rats with AICN at weeks 12, 16 and
20 (Fig. lb, ld). Increased laminin staining of the GBM was
Fig. 1. Immunohistochemical staining of glomeruli for laminin (A,B), s-laminin (C,D), type / collagen (E,F), type IV collagen (G,H), fibronectin (!,J),
and heparan sulfate proteoglycan (K,L) in normal Lewis rats (A,C,E,G,I,K) and in rats with AICN at week 20 (B,D,F,H,J,L) after disease induction. In
rats with AICN there is increased staining of the GBM in a "spike-like" pattern (B,D,J; arrows) for laminin, s-laminin, fibronectin, and heparan sulfate
proteoglycan (B,D,J,L). In addition, there is increased mesangial staining and GEC staining for fibronectin in AICN (J). No significant glomerular
staining is observed at AICN week 20 if the primary monoclonal antibody is omitted (M) or the primary polyclonal antibody replaced by normal rabbit
IgG (N). Immunoperoxidase with methyl green counterstain, x400. Insert in Fig. ID: >< 1000, inserts in Fig. lB and J: x 1500.
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observed in a similar fashion with both the polyclonal anti-
laminin antibody (Fig. ib) and with the monoclonal antibody
specific for the laminin B2 chain (data not shown). Basement
membrane staining frequently occurred in an irregular, spike-
like fashion (Fig. lb,dj and insert in Fig. id). Increased
glomerular immunostaining for s-laminin was not due to the
detection of rat IgG deposits along the GBM by the secondary
antibody (biotinylated horse anti-mouse IgG) as no glomerular
staining was observed at AICN week 20, when the primary
s-laminin antibody was omitted (Fig. im).
No glomerular expression of type I collagen was observed
throughout the course of AICN, although some periglomerular
fibrosis developed (Fig. 10. Similarly, the glomerular staining
pattern for type IV collagen did not appear different from
A L¼
C
Fig. 2. Glomerular ultrastructure in rats with A!CN at week 8 (A) and
at week 20 (B). At week 8 there are spike-like projections of the GBM
(arrows) interspersed between subepithelial immune complexes.
Podocyte ("p") foot processes are distorted and fused (A). At week 20
the spike-like projections of the GBM are more prominent and fre-
quently surround the subepithelial immune complexes (arrows). Abbre-
viations are: u, urinary space; c, capillary lumen. A x6000, B x9000.
normal controls when examined either by immunoperoxidase
staining (Fig. lh) or by the more sensitive immunofluorescent
staining method (data not shown).
Glomerular staining for fibronectin was not altered prior to
week 12. At weeks 12, 16, and 20, there were focal increases of
staining in a widened GBM (Fig. lj). Basement membrane
staining occurred in an irregular, spike-like pattern (Fig. lj).
Furthermore, after week 12, mesangial staining increased in a
diffuse pattern (Fig. lj). Faint staining of the GBM for entactin!
nidogen was noted at weeks 12, 16 and 20, while the remainder
of the glomerular tuft showed no abnormal staining (data not
shown). Heparan sulfate proteoglycan immunostaining showed
focal, irregular increases in the GBM at weeks 12, 16 and 20
(Fig. 11).
Matrix protein gene expression in glomeruli of rats with
AICN
As described elsewhere [45] and confirmed in this study, the
cDNAs for the various ECM proteins detected bands of the
I'
. .
E'0
predicted sizes in total glomerular RNA during Northern anal-
ysis (data not shown). Figure 3 depicts the results of slot blot
analysis of glomerular RNA obtained from rats with AICN for
the expression of the various ECM protein mRNA's. In the
case of laminin B2 chain and s-laminin mRNA, an initial
decrease at week 4 was followed by increased glomerular
expression at week 12. A very weak transcript of type I collagen
mRNA (likely to be derived from extraglomerular tissue) was
detected upon slot blot analysis of normal glomerular RNA,
allowing for the normalization of glomerular mRNA levels
measured at later time points of the disease. Type I collagen
mRNA was found to be increased at all time points examined,
peaking at week 12 (Fig. 3). In contrast, no increase of the
expression of glomerular type IV collagen mRNA was observed
at any time point (Fig, 3).
ECM protein immunostaining in glomeruli of rats with PHN
In order to assess whether any of the alterations in ECM
component gene or protein expression found in AICN were
mediated by complement, the studies of protein deposition and
glomerular gene expression were repeated in rats with PHN
with and without complement depletion by CVF. Unlike AICN,
no significant alterations in glomerular morphology or GBM
expansion were seen in PHN during the study period. Marked
proteinuria was present at day 5 (163 70 mg124 hrs) and
persisted thereafter.
No significant changes from the normal glomerular staining
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Time, weeks after induction of AICN
Fig. 3. Glomerular gene expression of laminin B2-chain (U), s-laminin
(S), type I (U) and type IV (0) collagen in rats at various stages of
A1CN. Results are mean SD (N = 3) of slot blot readings and are given
as densitometry readings compared to that observed with glomerular
RNA from normal rats. Prior to this all readings were normalized for
equivalent 28S ribosomal RNA which was measured using a specific
28S cDNA probe (Methods).
0 4 8 12
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Fig. 4. immunohistochemical glomerular
staining for type I collagen in rats with PHN
at day 5, showing positive staining in several
cells in GEC positions (arrows), Positive
staining is confined to the cytoplasm of GECs
(insert; arrow). Immunoperoxidase with
methyl green counterstain. x400, insert
>(l000.
pattern for laminin were observed in PHN prior to day 15. At
day 15 there was increased cytoplasmic laminin staining in rare
GEC, but no change of GBM staining was observed. S-laminin
immunostaining remained unchanged in PHN at all time points
examined. Furthermore, no changes of glomerular laminin and
s-laminin staining were observed in complement depleted rats
with PHN at day 5.
Staining for type I collagen in PHN became positive in the
glomerulus as early as day 3. Type I collagen staining appeared
to be confined to the cytoplasm of cells and no definite
mesangial matrix staining could be demonstrated (Fig. 4).
Neither immunoperoxidase (Fig. 4) nor immunofluorescent
(data not shown) staining revealed the presence of type I
collagen in the GBM. Most of the positive cells appeared to be
GEC, as suggested by their location at the periphery of the
capillary loops (Fig. 4). The number of positive cells at the edge
of the glomerular tuft showed a significant (P < 0.05) increase in
PHN at day 3 (1.9 1.1 cells/glomerular cross section vs. 0.0
0.0 in controls), peaked at days 5 (4.4 1.7 cells) and 10(4.5
2.3 cells), and decreased at day 15 (0.7 0.5 cells). Comple-
ment depletion prior to disease induction prevented the changes
observed at day 5 (0.2 0.2 cells). In contrast to type I
collagen, no discernible alterations of the immunostaining for
type IV collagen were observed during the course of PHN or in
complement depleted rats with PHN.
With fibronectin and entactin/nidogen, no changes of the
glomerular staining pattern were noted. In later stages of PHN
(days 10 and 15) a minor decrease of the GBM staining intensity
for heparan sulfate proteoglycan was observed (data not
shown). No changes in glomerular fibronectin, entactin/nidogen
and heparan sulfate proteoglycan staining were observed in
complement depleted rats with PHN at day 5.
Matrix protein gene expression in glomeruli of rats with PHN
As shown in Figure 5A, the glomerular expression of mRNA
for laminin and s-laminin increased to a minor degree at day 3
and 5 (s-laminin), while it remained unchanged or decreased at
the remaining time points. None of the changes reached the
level of statistical significance. Similarly, the glomerular
expression of type IV collagen mRNA remained unchanged or
decreased throughout the course of PHN (Fig. 5A). In contrast,
de novo expression of glomerular type I collagen mRNA was
noted at days 3, 5 and 10 after disease induction (Fig. SB). In
complement depleted rats, studied at day 5 after induction of
PHN, the glomerular mRNA levels for laminin, s-laminin, and
type IV collagen uniformly decreased compared to control rats
with PHN (Fig. 5A). Furthermore, in complement-depleted
PHN rats the expression of type I collagen mRNA in glomeruli
was reduced, although not completely abolished, in comparison
to rats with PHN at day S (Fig. SB).
Release of lamininfrom GEC following sublytic antibody-
and complement-mediated injury
Because the increase in laminin and s-laminin deposition and
gene expression observed in AICN did not occur acutely in
PHN where complement effects could be studied, we also
examined the effects of C5b-9 on laminin synthesis and gene
expression by GEC in culture.
Table 1 shows that neither anti-Fxla and complement medi-
ated GEC injury nor incubation of GEC with normal sheep IgG
and/or complement resulted in an increased release of laminin
into the cell culture medium. These results remained unchanged
when times and temperature of both antibody and complement
exposure were varied or when the incubation time after anti-
body stimulation was changed (data not shown). In contrast,
after stimulation of the GEC with PMA, laminin release was
enhanced 1.6-fold. These results remained unchanged when
protease inhibitors (10 mr'i n-ethylmaleimide, 1 mr's phenyl-
methyl-sulfonyl fluoride, 2.5 mts EDTA, 10 jsg/ml pepstatin;
final concentrations; all obtained from Sigma) were added to the
medium prior to freezing (data not shown). The lack of detect-
able laniinin release after stimulation of the GEC with antibody
and complement was not due to lethal cell injury, as no
increased LDH release into the medium was detectable after 90
minutes or 72 hours of stimulation. Furthermore, no differences
of the DNA content per well could be detected after 72 hours of
incubation under the various conditions.
Immunofluorescent staining of cultured GEC for cellular
laminin showed positive cytoplasmic staining (Fig. 6), similar to
that reported by others in rat niesangial cells [461. Antibody and
C5b-9 attack did not alter GEC laminin staining. Attempts to
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Fig. S. Glomerular gene expression of laminin B2-chain (, s-laminin (•), and type IV collagen (0) (A) and type! collagen (B) in rats at various
stages of PHN. Results are mean SD (N = 3) of Northern analyses and are given as densitometry reading compared to that observed with
glomerular RNA from normal rats. Prior to this all readings were normalized for equivalent 28S ribosomal RNA which was measured using a
specific 28S cDNA probe (Methods). "5/CVF"-complement depleted rats at day 5 of PHN. Relative levels of type I collagen mRNA are not
depicted in A because the absence of detectable glomerular type I collagen mRNA in normals precluded normalization of the results.
Table 1. Laminin concentration in the cell supernatant and cellular expression of laminin B2 chain mRNA 72 hours after stimulation of GEC
with antibody (anti-FxIA or normal sheep IgG) and complement (non-heated or heat inactivated) or PMA (positive control)
Condition
Normal sheep
Anti-FxIA + Anti-FxlA + Normal sheep IgG + inact.
Medium compl. inact. compl. IgG + compl. compl. PMA
Laminin in GEC
supernatant % of medium 100 95 24 95 20 100 13 100 157 18N= 8 8 8 6 2 3
P vs. medium — ND ND ND ND <0.05
Laminin B2 mRNA
in GEC % of mediuma 100 95 67 91 50 85 43 90 74 138 19
N= 6 6 6 6 6 3
P vs. medium" — ND ND ND ND
s-Laminin mRNA
in GEC % of mediuma 100 48 16 49 12 57 13 49 16 144 14
N=b 3 3 3 3 3 3
Data are mean so. Abbreviation is: ND, not determined. Absolute concentration of laminin in the culture medium of non-stimulated GEC's
was 1.65 1.03 ng4tg DNA at 72 hours.
a Results are given as densitometry readings of slot blots compared with those obtained in unstimulated GEC RNA. Prior to this all readings were
normalized for equivalent 28S ribosomal RNA which was measured using a specific 28S cDNA probe (see Methods).
b Bonferronal t-tests. In cases of 3 observations only no statistical significance was calculated.
measure laminin in cellular extracts or in the cell layer using a
variety of extraction methods yielded inconsistent results and
usually the laminin content in the extract was below the
detection threshold of the laminin ELISA (data not shown).
Laminin B2-chain mRNA in GEC's after sublytic antibody-
and complement-mediated injury
Both laminin B2-chain and s-laminin mRNA were detectable
in RNA isolated from non-stimulated GEC (Table 1). However,
neither the cellular expression of laminin B2-chain nor of
s-laminin mRNA increased after GEC injury with anti-Fx1A
and complement, but rather decreased in the case of s-laminin
mRNA (Table 1). Similarly, no increase was observed after
GEC stimulation with normal sheep IgG and complement. In
contrast, stimulation of GEC with PMA resulted in a 1.4-fold
Fig. 6. Immunofluorescent staining of cultured rat GEC for laminin
showing positive cytoplasmic staining. x400.
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increase of laminin B2-chain and s-laminin mRNA expression
(Table 1).
Discussion
In the present study we have analyzed the sequential changes
of ECM proteins, including laminin, s-Iaminin, type I and IV
collagen, fibronectin, entactin/nidogen, and heparan sulfate
proteoglycan, in the AICN model of chronic MN. The results
show that several of the proteins examined accumulated in the
GBM during the course of AICN. For most ECM proteins the
staining pattern in the expanded GBM was suggestive of
preferential accumulation in "spikes".
On the basis of observations in human MN [11—13,47—49] and
in experimental autoimmune glomerulonephritis in mice [10], it
has been suggested that GBM thickening in MN reflects in part
laminin accumulation along the outer surface of the GBM and
that laminin may be a major constituent of the subepithelial
"spikes" [10, 11]. However, no previous studies have ad-
dressed this issue in AICN which is generally regarded as the
experimental model most analogous to human MN. Our finding
of a marked increase in laminin immunostaining in the GBM of
AICN rats is consistent with the findings in humans and other
models with subepithelial immune complex deposits. The par-
allel rise in glomerular laminin B2-chain mRNA levels during
AICN suggests that the increase in laminin protein was at least
partially due to augmented synthesis. In contrast to laminin,
little is currently known about the recently described s-laminin,
which is restricted to glomerular and vascular basement mem-
branes [16] and which is of uncertain cellular origin in the
glomerulus. Our findings show that in comparison to laminin, an
even more pronounced increase of s-laminin protein and gene
expression occurred in glomeruli of AICN rats. The observa-
tion of a spike-like accumulation of s-laminin on the outer
surface of the GBM suggests that GEC's are the likely source of
the increased s-laminin synthesis. Furthermore, the cell culture
data of the present study demonstrate that GEC's have the
capability to produce s-laminin mRNA. In analogy to the
greater increase of s-laminin than laminin synthesis in AICN,
previous data obtained by Koide and Horikoshi [50] are of
interest. These investigators raised monoclonal antibodies
against laminin, one of which (Lam3) reacted exclusively with
mesangial but not with GBM laminin in the normal human
kidney. In patients with MN, however, Lam3 also stained the
GBM and the authors concluded that a conformational change
of the laminin deposited in pathological basement membrane
had occurred [50].
In the present study neither the glomerular protein nor gene
expression of type IV collagen increased during the course of
AICN. Data on the immunohistochemical staining for type IV
collagen in both human and murine MN are conflicting: while
some authors reported an increase of this collagen type in the
GBM [13], others have not been able to confirm this [10, 11]. An
explanation for these apparently contradictory findings has
recently been provided by Kim et al [12], who observed a
selective increase of novel chains of type IV collagen
[a3(IV)NC, a4(IV)NC and Alport antigen] in the "spikes" of
patients with intermediate stages of MN, while an increase of
traditional type IV collagen [al(IV)2, c2(IV)1] was confined to
late disease stages and to the subendothelial region of the GBM.
These latter findings suggest that despite the capability of
cultured GEC to produce type IV collagen [47, 51, 52], the
increased type IV collagen immunostaining in human MN may
be due to production by glomerular endothelial cells. Whether
this occurs in AICN as well cannot be determined from the
present study, since only early and intermediate stages of the
disease were investigated.
Similar to type IV collagen, no increase of the glomerular
immunostaining for interstitial type I collagen occurred in rats
with AICN. In contrast, mRNA levels for type I collagen
increased sixfold at week 12 of AICN. This increase may,
however, have been falsely exaggerated compared to other
matrix components by the very weak signal for type I collagen
mRNA obtained in normal glomerular RNA, which was used as
a denominator during the normalization of the densitometry
readings. Consequently, the absolute increase in type I collagen
transcript numbers is likely to be small. The relevance of the
increased expression of glomerular type I collagen mRNA
during AICN is therefore unclear. One possibility is that the
mRNA analyzed is not entirely of glomerular origin. However,
we have also observed de novo expression of type I collagen in
GEC from remnant kidneys [53] and Salant et a! have previ-
ously reported similar findings in the PHN model of MN by
both Northern analysis and in situ hybridization [54]. Others
have demonstrated occasional banded collagen fibrils, indica-
tive of interstitial collagen fibrils, in the subepithelial space of
AICN rats after 12 to 24 weeks [6]. In situ hybridization for type
I collagen mRNA will be necessary to establish the presence or
absence of this mRNA species in AICN. In contrast to AICN,
in the PHN model we observed not only an increase in
glomerular mRNA for type I collagen but also a complement
dependent increase of the protein in GEC cytoplasm, further
supporting the notion that these cells are capable of synthesiz-
ing interstitial type collagens in vivo. The relevance of the
transient intracellular GEC expression of type I collagen to
either proteinuria or ECM accumulation in PHN, however,
remains unclear, as we have not been able to demonstrate
conclusively the occurrence of type I collagen in the GBM or
the glomerular ECM. Although interstitial types of collagen
(types I or III) can be expressed in glomeruli of various
progressive renal diseases [13, 55—57], so far only one study has
reported the appearance of interstitial collagen (type III) in
glomeruli during MN [55], while other studies were negative
[13, 57]. The study demonstrating an accumulation of interstitial
collagen [55] showed one of two MN patients with very rare
deposits of type III collagen, which were confined to the
mesangium. Thus, it seems unlikely that interstitial type colla-
gens play a significant role in the pathogenesis of MN. Rather
the appearance of glomerular type I or type III collagen in MN
appears to be limited to advanced stages where mesangial
sclerosis has developed.
Analogous to our findings in AICN, increased staining of the
GBM for fibronectin has been observed in human MN [13],
although others [10, 121 have been unable to confirm this. As in
the case of the fibronectin present in normal GBM, the origin of
the increased fibronectin in the basement membrane of AICN
rats remains speculative. Thus, GBM fibronectin might be
derived either from local synthesis by mesangial or endothelial
cells [52, 58] or it may originate from circulating fibronectin,
which is trapped in the basement membrane [59, 60].
GBM staining for entactin/nidogen also increased during
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AICN, although to a lesser degree than for laminin, s-laminin or
fibronectin. Increased entactin staining in AICN may in part
reflect the fact that entactin and the laminin B2-chain are known
to co-localize in the kidney [61], probably due to stable complex
formation between these two molecules [60]. Similar to our
experimental data, entactin immunostaining has been observed
to increase in the "spikes" of human MN as well [12, 61].
The final ECM protein investigated in AICN, heparan sulfate
proteoglycan, also showed a marked increase in the GBM of
AICN rats, a finding in agreement with observations in human
MN [131. Cell culture data obtained in human GEC have shown
that these cells can produce three distinct types of heparan
sulfate proteoglycans [62]. Our finding of an increased expres-
sion of heparan sulfate proteoglycan in the GBM of AICN rats
is consistent with physiologic studies in human MN, which
suggests that altered glomerular permeability in this disease is
primarily a consequence of large pore defects in the size-
selective barrier to protein filtration rather than a charge defect
[14]. This finding is in contrast to the results reported in
aminonucleoside nephrosis where a decrease in heparan sulfate
proteoglycan content and mRNA has been reported [63, 64].
It is now well established that the initial increase in glomer-
ular permeability to protein which occurs in experimental MN
is mediated by insertion of the complement membrane attack
complex, C5b-9, into the GEC membranes [reviewed in 4, 5].
With regard to altered GBM permeability induced by passive
administration of anti-GEC antibody (anti-Fx1A), C5b-9 has
been implicated as the principal mediator in the intact animal
[65], the isolated perfused kidney 166], and in isolated glomeruli
exposed to anti-Fx1A and complement in vitro [67]. In AICN
induced by active immunization with FxlA, the close similarity
of immunopathological features to those in PHN [6, 19], similar
properties of the deposited antibodies [68, 69] and unique
excretion of C5b-9 in the urine [27, 28] all suggest that the initial
alteration in glomerular permeability in this model is also C5b-9
mediated. However, to assess the role of complement in
producing the ECM changes observed in chronic AICN, it was
necessary to study the PHN model where the onset of protein-
uria is much more rapid and selective complement depletion
studies can be carried out. Unfortunately, we have been unable
to document any substantial changes in ECM composition in
PHN acutely. These data confirm recent findings of Fogel et al
[70], who reported that glomerular laminin, type IV collagen
and fibronectin protein and mRNA levels remained unchanged
in rats with PHN at 1, 3 or 12 weeks. The absence of a
demonstrable increase in ECM deposition in early PHN does
not exclude an effect of C5b-9 on ECM component gene
expression which might translate into increased matrix deposi-
tion chronically. However, studies of ECM gene expression in
PHN revealed a decrease rather than increase in most matrix
component mRNA levels in the early C5b-9 mediated phase of
this disease. This may reflect an early severe phase of GEC
injury induced by a single large dose of anti-GEC antibody with
some accompanying GEC lysis and detachment that is not seen
in the more insidious AICN model.
Sublytic C5b-9 attack on cultured glomerular cells can be a
potent stimulus for cell activation including production of
oxidants by mesangial cells and prostaglandins by mesangial
and epithelial cells [71—73]. Torbohm et al [51] reported a
16-fold increase in type IV collagen production by both human
and rat GEC in vitro following direct, sublytic CSb-9 attack but
did not study antibody-induced complement activation or lami-
nm production. We therefore tested the effect of sublytic CSb-9
attack induced by anti-Fx1A antibody, a mechanism presum-
ably analogous to what occurs in vivo, on production of laminin
by GEC in culture. However, our findings did not suggest any
measurable effect of C5b-9 on laminin or s-laminin gene expres-
sion or laminin protein release by the rat GEC. In preliminary
experiments we have also failed to detect an effect of C5b-9 on
type IV collagen mRNA expression by the GEC (W.G. Couser,
unpublished data). Differences between this study and that of
Torbohm et al [51] with respect to the mechanism of comple-
ment activation and the amount of C5b-9 generated preclude
any meaningful comparison of these results. However, our
findings in GEC cultures are consistent with our in vivo data
and those of Fogel et al [70] that suggest no effect of C5b-9 on
GEC expression of genes for ECM proteins that are overex-
pressed in MN.
Our findings also suggest that alterations in ECM component
synthesis and gene expression follow, rather than precede,
proteinuria. Thus, proteinuria was apparent at five days in PHN
whereas detectable alterations in ECM staining and mRNA
levels were not seen. This finding suggests that the defect in
glomerular barrier function induced by C5b-9 is not a conse-
quence of any alteration in GBM matrix component synthesis,
a conclusion which accords with the observation that altered
GBM permeability can be induced by C5b-9 within minutes of
activation [67]. This sequence of altered permeability occurring
prior to, and independent of, any change in the synthesis of
ECM components also provides evidence that the stimuli which
lead to changes in GEC ECM component synthesis may be
different from those which result in proteinuria. However, we
cannot exclude the possibilities that more chronic exposure to
C5b-9 than we studied in PHN and cultured GEC may contrib-
ute to the changes described after several weeks in AICN and
human MN or that ECM changes too small to be detected by
our techniques precede proteinuria. Another mechanism that
could be involved in the occurrence of a small but rapid change
of the GBM composition is the release of a recently described
gelatinase from GEC [30]. Studies by Watanabe et al [74] have
shown a substantial upregulation of an apparently similar gelat-
inase in glomeruli obtained early in PHN. Thus, C5b-9 induced
release of a GBM degrading proteinase might result in altered
permeability due to a degradation rather than decreased syn-
thesis of normal matrix components.
In summary, our studies document an increase in GBM
content of several ECM components in chronic experimental
MN (AICN), particularly laminin and s-laminin but also includ-
ing fibronectin, entactin/nidogen and heparan sulfate proteogly-
can. Glomerular mRNA was also more abundant for laminin
and s-laminin and also for type I collagen, which was not found
in increased quantity. In the more acute PHN model of MN,
type I collagen was the only ECM component with increased
mRNA levels and accompanied a transient increase in type I
collagen staining in GEC cytoplasm. Antibody induced C5b-9
attack on cultured GEC did not increase laminin or s-laminin
mRNA or laminin release into the culture medium. These
findings suggest that the mechanisms which lead to ECM
accumulation in the GBM in chronic MN may be different from
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the CSb-9 mediated process which causes proteinuria and
initiates the disease.
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